Seegene Inc (096530) - Total Liabilities

Latest as of June 2026: ₩226.66 Billion KRW ≈ $153.60 Million USD

Based on the latest financial reports, Seegene Inc (096530) has total liabilities worth ₩226.66 Billion KRW (≈ $153.60 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 096530 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Seegene Inc - Total Liabilities Trend (2012–2025)

This chart illustrates how Seegene Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Seegene Inc (096530) total assets.

Seegene Inc Competitors by Total Liabilities

The table below lists competitors of Seegene Inc ranked by their total liabilities.

Company Country Total Liabilities
FS Credit Opportunities Corp.
NYSE:FSCO
USA $720.95 Million
Burke & Herbert Financial Services Corp. Common Stock
NASDAQ:BHRB
USA $7.07 Billion
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
China CN¥1.05 Billion
Scandi Standard publ AB
ST:SCST
Sweden Skr4.96 Billion
Ye Chiu Metal Recycling China Ltd
SHG:601388
China CN¥1.56 Billion
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
China CN¥942.80 Million
Altareit
PA:AREIT
France €2.67 Billion
Helix Energy Solutions Group Inc
NYSE:HLX
USA $1.06 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Seegene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 096530 net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.62 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.22 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.18 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seegene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seegene Inc (2012–2025)

The table below shows the annual total liabilities of Seegene Inc from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 ₩219.98 Billion
≈ $149.08 Million
-1.71%
2024-12-31 ₩223.80 Billion
≈ $151.67 Million
+1.24%
2023-12-31 ₩221.05 Billion
≈ $149.80 Million
-9.03%
2022-12-31 ₩243.01 Billion
≈ $164.68 Million
-40.49%
2021-12-31 ₩408.31 Billion
≈ $276.71 Million
-9.11%
2020-12-31 ₩449.26 Billion
≈ $304.46 Million
+940.74%
2019-12-31 ₩43.17 Billion
≈ $29.25 Million
+20.65%
2018-12-31 ₩35.78 Billion
≈ $24.25 Million
-10.10%
2017-12-31 ₩39.80 Billion
≈ $26.97 Million
-39.37%
2016-12-31 ₩65.65 Billion
≈ $44.49 Million
+11.35%
2015-12-31 ₩58.96 Billion
≈ $39.95 Million
+35.17%
2014-12-31 ₩43.62 Billion
≈ $29.56 Million
-2.19%
2013-12-31 ₩44.59 Billion
≈ $30.22 Million
+7.00%
2012-12-31 ₩41.68 Billion
≈ $28.24 Million
--

About Seegene Inc

KQ:096530 Korea Biotechnology
Market Cap
$1.04 Billion
₩1.54 Trillion KRW
Market Cap Rank
#8731 Global
#225 in Korea
Share Price
₩33700.00
Change (1 day)
+3.85%
52-Week Range
₩21850.00 - ₩35650.00
All Time High
₩140042.88
About

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more